title: [Clinical analysis about the management and the perinatal outcomes of pregnancy with chronic myeloid leukemia].
abstract: OBJECTIVE
  to investigate the perinatal outcomes of pregnancy with chronic myeloid leukemia (CML) and how to manage it during pregnancy.
  
  
  METHODS
  to retrospectively analyse the clinical datas about the perinatal outcome and the obstetric management of the 16 cases of pregnancy with CML during the last 30 years in a single center.
  
  
  RESULTS
  (1) management ang perinatal outcomes: among the 16 pregnancies nine ended with therapeutic abortion during the first or second trimester and no CML complications were observed. The average gestation week was 7 weeks (5 - 13 weeks) when they came to our hospital. Seven pregnancies gave birth, among which CML was diagnosed during pregnancy in four patients and pregnancy was confirmed during CML in three patients. The average gestation week was 36 weeks (27 - 40 weeks(+2)) when they came to our hospital. Among the seven women three were treated with hydroxyurea (one became pregnant while she was on hydroxyurea and she elected to continue her pregnancy and continued to use hydroxyurea), one with leukapheresis twice after her 40 weeks of gestation, one with plateletpheresis and three hadn't any treatment. In the seven pregnacies three developed severe pre-eclampsias, including the two had hydroxyurea during the gestation. The average delivery gestational week was 38 weeks (33 weeks(+4) - 41 weeks), two were premature birth. Two caesarean sections, three vaginal deliveries and two forceps deliveries. There were two postpartum hemorrhage, during the 24 hours the amount of bleeding was 1500 - 1800 ml and secondary disseminated intravascular coagulation happened. Seven patients gave birth to seven infants whose average birth weight was 2469 g (1820 - 2810 g), of whom two were premature infants, two low birth weight infants, one had congenital malformation and two had abnormal blood routine examinations. (2) Management after delivery and prognosis: during the nine patients who ended pregnancy with therapeutic abortion during the first or second trimester four withdraw, one died whose course of disease was 3 years and the other four were alive during 5 months to 72 months, among which one had stem cell transplantation, two are taking imatinib mesylate and one takes hydroxyurea. Among the seven patients who deliveried two withdraw, two died and three are alive. Among the seven infants two withdraw, the other five have normal development following 4 months to 9 years.
  
  
  CONCLUSIONS
  CML patient may have successful pregnancy and delivery, and it is not the absolute indication for terminating pregnancy. On the other hand, CML and the treatment during pregnancy can have side effect on the mother and the fetus, so the patients should be monitored and treated in tertiary hospitals.
authors.affiliation: Department of Obstetrics, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Da-Peng
authors.initials: DP
authors.lastname: Wang
authors.forename: Mei-Ying
authors.initials: MY
authors.lastname: Liang
authors.forename: Xiao-Hong
authors.initials: XH
authors.lastname: Zhang
authors.forename: Shan-Mi
authors.initials: SM
authors.lastname: Wang
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001549:Benzamides; D001707:Biopsy, Needle; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D000068877:Imatinib Mesylate; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007937:Leukapheresis; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D007958:Leukocyte Count; D010879:Piperazines / Q000627:therapeutic use; D011225:Pre-Eclampsia / Q000209:etiology; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D011256:Pregnancy Outcome; D011261:Pregnancy Trimester, First; D011263:Pregnancy Trimester, Third; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D006918:Hydroxyurea